CTCs & Liquid Biopsy: Solutions for Fast and Accurate Diagnosis
Enrichment of rare cell populations such as Circulating Tumor Cells (CTCs) from blood samples is essential for diagnostics and the subsequent development of truly effective treatment programmes. MMI technologies are widely utilized for the detection and isolation of circulating tumor cells from liquid biopsies to determine the tumor mutational burden, to detect copy number variations or to identify novel biomarkers. Thus, our products support fast and accurate diagnosis, target-specific treatments and their effective monitoring. Researchers isolate pure cell populations for their subsequent analysis in genomics, transcriptomics and proteomics.
"At Simfo, we are interested in analyzing molecular profile of circulating tumor cells (CTCs), because CTCs reflect the real status of tumor genotypes. CTCs exhibit high heterogeneity within a patient and for this reason we analyze individual CTCs for KRAS, BRAF and EGFR mutations. The MMI CellEctor instrument allows us to precisely select single CTCs from patient samples in order to individually analyze their genomic integrity – an important pre-requisite for our research."